TAmiRNA GmbH is a biotech company specialized in the identification and validation of non-coding RNAs as biomarkers for age-related diseases. The mission of TAmiRNA is to provide clinically useful biomarkers to improve and prolong patient stability, health and quality of life with increasing age.
TAmiRNA specializes in technologies for profiling levels of blood-circulating microRNAs and developing multi-parametric classification algorithms (“signatures”). . TAmiRNA uses these technologies to develop minimal-invasive diagnostic tests for early diagnosis and prognosis of disease, or as companion diagnostic tests to support treatment decisions.
TAmiRNA’s technologies are based on research observations that so-called “circulating microRNAs” are secreted from cells and freely floating blood, where they are protected from degradation by vesicular encapsulation.
Subject of numerous IP filings between 2010 and 2016, TAmiRNA’s core proprietary technologies relate to:
- A microRNA panel for diagnosis and treatment of bone disorders such as osteoporosis
- MicroRNA-31 for diagnosis and treatment of bone and cardiovascular disorders
- A microRNA panel for the analysis of platelet activation in patients that can be used to monitor efficacy of anti-platelet therapies.
Products and Services
TAmiRNA uses its technology for the discovery and validation of circulating microRNAs as biomarkers for age-related diseases. The pipeline includes developments in osteoporosis, cardiovascular disease, type-2 diabetes, and cancer.
These biomarkers have been selected based on their utility for early diagnosis or prognosis of disease, and can be used to identify stratified patient subgroups that share similar disease profiles and therefore medical needs.
TAmiRNA ‘microRNA kit’ solutions enable users to quantify the levels of specific microRNA combinations in serum, plasma, urine or other biofluids. The company initially developed kits for bone disease (osteomiR) and cardiovascular disease (thrombomiR).
TAmiRNA offers contract research services for companies in need of targeted biomarker development. Customers include (bio)pharmaceutical companies with drug development programs in human and veterinary medicine, Medtech companies and clinical research groups.
TAmiRNA supports its clients by providing one-stop-shop solutions for biomarker development and industrialization, including the discovery, validation and industrialization of biomarker candidates.
TAmiRNA has also implemented a wide range of analytical and technology services for analysis of non-coding RNAs including transcriptomic analyses such as quantitative PCR, digital PCR, microarray, and next generation sequencing as well as cell-based assays for deciphering microRNA function.
Structure and background
TAmiRNA’s founders, Matthias Hackl, Otto Kanzler, Regina & Johannes Grillari share a strong interest in musculoskeletal disorders, especially osteoporosis, and cardio-vascular disease along with a guiding vision “to bring more life into the age of human”. Their developments are designed to support stability and mobility of older people through more sensitive and specific tools for risk assessment of (age-related) diseases to enable early and effective interventions.
TAmiRNA was founded in November 2013 with pre-seed funding attracted the previous summer. Further seed funding arrived a year later, hard on the heels of an investigator award from the American Society for Bone and Mineral Research (ASBMR) and the European Calcified Tissue Society (ECTS).
In May 2015, TAmiRNA was runner-up in the Best of Biotech International Awards. Later that year, the company received Phase 1 funding for its SME instrument and was also named HighTec winner in the GEWINN Young Entrepreneur Awards.
During 2016, TAmiRNA rolled out it s first products, the osteomiR ‘research use only’ kit for osteoporosis.
The company is privately owned, with headquarters in Vienna.
Standards and Compliance
While it research-use products do not need comply with regulatory standards, TAmiRNA nevertheless takes quality and compliance very seriously. Its OEM equipment manufacturing partners are ISO 13485 certified, allowing TAmiRNA to supply products that are CE-compliant.
During 2014, TAmiRNA acquired Exiqon A/S “Center of Excellence” status which has been in 2014. All quality ad compliance aspects are regularly assessed by internal and external audits.
TAmiRNA has implemented a Quality Management System according to ISO 9000/9001 guidelines.
To learn more about TAmiRNA’s specialist capabilities and services and how they can assist your business, please contact the supplier directly.
- > TAmiRNA partners with SimplicityBio to create new biomarker offers
- > TAmiRNA’s osteomiR™ and thrombomiR™ microRNA qPCR laboratory testing service
- > thrombomiR™ microRNA qPCR test kit
- > Early diagnosis of osteoporosis
- > TAmiRNA to exhibit microRNA capabilities at BIO-Europe
- > TAmiRNA to host microRNA analysis workshop from Vienna
- > osteomiR™ testing kit
- > TAmiRNA unveils osteoporosis microRNA testing kit at ASBMR
- Clinical Trials & Studies
- Drug Discovery
- Pre-Clinical Research